Results 291 to 300 of about 9,044,537 (408)

Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current Challenges. [PDF]

Ther Drug Monit
Carrara S, Widmer N, Rodino F, Du L, Briki M, Decosterd LA, Marzolini C, Buclin T, Thoma Y, Guidi M.   +9 more
europepmc   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Therapeutic drug monitoring plays an important role in patients with noninfectious uveitis receiving adalimumab. [PDF]

Front Immunol
Cheng W, Xiao J, Li S, Wang H, Wang S, Qian Y, Zhao C, Gao F, Qin X, Zhang M.   +9 more
europepmc   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Toward personalized therapeutic drug monitoring of ustekinumab in Crohn's disease: influence of previous exposure to biologics. [PDF]

Therap Adv Gastroenterol
Kwon Y, Kim YZ, Jeong TJ, Kim SY, Kim H, Kim ES, Choe YH, Kim MJ.   +7 more
europepmc   +1 more source

Correction: Comparison of bulk and microfluidic methods to monitor the phase behaviour of nanoparticles during digestion of lipid-based drug formulations using in situ X-ray scattering

, 2019
Linda Hong, Muhsincan Şeşen, Adrian Hawley, Adrian Neild, Patrick T. Spicer, Ben J. Boyd   +5 more
openalex   +2 more sources

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source

Therapeutic drug monitoring of biologics in inflammatory bowel disease: An evidence-based multidisciplinary guideline. [PDF]

Acta Pharm Sin B
Shi C, Zhou H, Zhu L, Miao L, Yang H, Wu K, Zhang B, He J, Chen M, Cao Q, Liang J, Mao R, Chen X, Zhao R, Zhang B, Lin H, Wang J, Lu X, Xia J, Yao X, Lin R, Chen M, Zhang Y.   +22 more
europepmc   +1 more source